Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii

References

• McConnell MJ, Actis L, Pachon J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37:130–55.
   PubMed Web of Science ®Google Scholar
• Biswas S, Brunel JM, Dubus JC, et al. Colistin: an update on the antibiotic of the 21st century. Exp Rev Anti-infective Therapy. 2012;10:917–34.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Rodriguez-Villalobos H, De Backer D, et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis. 2006;25:257–60.
   PubMed Web of Science ®Google Scholar
• Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009;30:257–63.
   PubMed Web of Science ®Google Scholar
• Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72:3277–82.
   PubMed Web of Science ®Google Scholar
• Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009;53:3628–34.
   PubMed Web of Science ®Google Scholar
• Beceiro A, Llobet E, Aranda J, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55:3370–9.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Adler B, et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3022–4.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–7.
   PubMed Web of Science ®Google Scholar
• Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593–656.
   PubMed Web of Science ®Google Scholar
• Zhang G, Meredith TC, Kahne D. On the essentiality of lipopolysaccharide to Gram-negative bacteria. Curr Opin Microbiol. 2013;16:779–85.
   PubMed Web of Science ®Google Scholar
• Peng D, Hong W, Choudhury BP, et al. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate. Infect Immunity. 2005;73:7569–77.
   PubMed Web of Science ®Google Scholar
• Steeghs L, den Hartog R, den Boer A, et al. Meningitis bacterium is viable without endotoxin. Nature. 1998;392:449–50.
   PubMed Web of Science ®Google Scholar
• Garcia-Quintanilla M, Carretero-Ledesma M, Moreno-Martinez P, et al. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii. Int J Antimicrobial Agents. 2015;46:696–702.
   PubMed Web of Science ®Google Scholar
• Garcia-Quintanilla M, Pulido MR, Moreno-Martinez P, et al. Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents and Chemother. 2014;58:2972–5.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Mansell A, et al. Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. Infect Immunity. 2013;81:684–9.
   PubMed Web of Science ®Google Scholar
• Beceiro A, Moreno A, Fernandez N, et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58:518–26.
   PubMed Web of Science ®Google Scholar
• Mu X, Wang N, Li X, et al. The effect of Colistin resistance-associated mutations on the Fitness of Acinetobacter baumannii. Front Microbiol. 2016;7:1715.
   PubMed Web of Science ®Google Scholar
• Henry R, Vithanage N, Harrison P, et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrobial Agents Chemotherapy. 2012;56:59–69.
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuenca F, Tomas-Carmona M, Caballero-Moyano F, et al. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin. 2013;31:4–9.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing; Twenty-seventh informational supplement. CLSI document M100-S27. Wayne, PA., USA: Clinical Laboratory Standards Institute; 2017
   Google Scholar
• McConnell MJ, Dominguez-Herrera J, Smani Y, et al. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immunity. 2011;79:518–26.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Pachon J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine. 2010;29:1–5.
   PubMed Web of Science ®Google Scholar
• O'Toole GA, Pratt LA, Watnick PI, et al. Genetic approaches to study of biofilms. Methods Enzymol. 1999;310:91–109.
   PubMed Web of Science ®Google Scholar
• Girardello R, Visconde M, Cayo R, et al. Diversity of polymyxin resistance mechanisms among Acinetobacter baumannii clinical isolates. Diagnostic Infect Dis. 2017;87:37–44.
   PubMed Web of Science ®Google Scholar
• Lean SS, Suhaili Z, Ismail S, et al. Prevalence and Genetic Characterization of Carbapenem- and Polymyxin-Resistant Acinetobacter baumannii Isolated from a Tertiary Hospital in Terengganu, Malaysia ISRN Microbiol. 2014;2014:953417.
   PubMedGoogle Scholar
• Selasi GN, Nicholas A, Jeon H, et al. Genetic basis of antimicrobial resistance and clonal dynamics of carbapenem-resistant Acinetobacter baumannii sequence type 191 in a Korean hospital. Infect Genet Evol. 2015;36:1–7.
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis. 2011;203:545–8.
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, et al. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother. 57:4587–9.
   PubMed Web of Science ®Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93.
   PubMed Web of Science ®Google Scholar
• Gaddy JA, Actis LA. Regulation of Acinetobacter baumannii biofilm formation. Future Microbiol. 2009;4:273–8.
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Rajenderan S, Laishram S, et al. Biofilm formation and motility depend on the nature of the Acinetobacter baumannii Clinical Isolates. Frontiers Public Health. 2016;4:105.
   PubMed Web of Science ®Google Scholar
• Becker KW, Skaar EP. Metal limitation and toxicity at the interface between host and pathogen. FEMS Microbiol Rev. 2014;38:1235–49.
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, Garcia-Quintanilla M, Labrador-Herrera G, et al. Impaired growth under iron-limiting conditions associated with the acquisition of colistin resistance in Acinetobacter baumannii. Int J Antimicrobial Agents. 2016;47:473–7.
   PubMed Web of Science ®Google Scholar
• Da Silva GJ, Domingues S. Interplay between Colistin resistance, virulence and fitness in Acinetobacter baumannii. Antibiotics. 2017;6:1–11.
   Web of Science ®Google Scholar
• Lesho E, Yoon EJ, McGann P, et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208:1142–51.
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, et al. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrobial Agents Chemotherapy. 2013;57:4587–9.
   PubMed Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Gupta J, et al. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res. 2013;23:1155–62.
   PubMed Web of Science ®Google Scholar
• Dahdouh E, Gomez-Gil R, Sanz S, et al. A novel mutation in pmrB mediates colistin resistance during therapy of Acinetobacter baumannii. Int J Antimicrobial Agents. 2017;49:727–33.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Del Franco M, Andini R, et al. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii. Diagnostic Microbiol Infect Dis. 2015;82:222–6.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Poulou A, Dafopoulou K, et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii. Antimicrobial Agents Chemotherapy. 2014;58:828–32.
   PubMed Web of Science ®Google Scholar
• Fernandez-Reyes M, Rodriguez-Falcon M, Chiva C, et al. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics. 2009;9:1632–45.
   PubMed Web of Science ®Google Scholar
• Maifiah MH, Cheah SE, Johnson MD, et al. Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii. Scientific Reports. 2016;6:22287.
   PubMed Web of Science ®Google Scholar